Voyager Therapeutics Announces Pricing of Public Offering
Summary
Oppenheimer & Co. is acting as book-running manager for the offering.The Company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and marketable securities, the $20.0 million the Company received from Novartis Pharma AG (Novartis) in January 2024 as consideration for the purchase of shares of its common stock and the additional $80.0 million upfront payment the Company anticipates receiving from Novartis in connection with the Companys entry into a strategic collaboration and a stock purchase agreement with Novartis in December 2023, to advance the Companys anti-tau antibody program for the treatment of Alzheimers disease (AD) and its SOD1 silencing gene therapy program for the treatment of amyotrophic lateral sclerosis (ALS) into clinical development, to advance its tau silencing gene therapy program for the treatment of AD and its anti-amyloid gene therapy program for the treatment of AD in preclinical development, to support its other preclinical development programs, and for working capital and other general corporate purposes.The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. Copies of the preliminary prospectus supplement, the final prospectus supplement, when available, and the accompanying prospectus relating to this offering may also be obtained, when available, by contacting Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146, Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com, and Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.About Voyager TherapeuticsVoyager Therapeutics is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of and ultimately cure neurological diseases. Many of the Companys programs are derived from its TRACER AAV capsid discovery platform, which the Company has used to generate novel capsids and identify associated receptors.Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the public offering, and other factors discussed in the Risk Factors section contained in the preliminary prospectus supplement related to the public offering and the Companys quarterly and annual reports filed with the SEC.All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made.